You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature
|
|---|---|
| Published in |
BMC Cancer, July 2015
|
| DOI | 10.1186/s12885-015-1536-y |
| Pubmed ID | |
| Authors |
Ning Jia, Fionnuala C. Cormack, Bin Xie, Zita Shiue, Behzad Najafian, Julie R. Gralow |
| Abstract |
Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis (FSGS) or its morphological variant, collapsing focal segmental glomerulosclerosis (CFSGS). We describe a breast cancer patient who developed heavy proteinuria (protein/creatinine ratio 9.1) and nephrotic syndrome following treatment with oral ibandronate for 29 months. CFSGS was proven by biopsy. There was no improvement 1 month after ibandronate was discontinued. Prednisone and tacrolimus were started and she experienced a decreased in proteinuria. In patient who develops ibandronate-associated CFSGS, proteinuria appears to be at least partially reversible with the treatment of prednisone and/or tacrolimus if the syndrome is recognized early and ibandronate is stopped. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 14% |
| Student > Master | 4 | 11% |
| Student > Bachelor | 4 | 11% |
| Researcher | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 7 | 19% |
| Unknown | 10 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 47% |
| Nursing and Health Professions | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Environmental Science | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 10 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2015.
All research outputs
#14,231,810
of 22,817,213 outputs
Outputs from BMC Cancer
#3,360
of 8,300 outputs
Outputs of similar age
#135,715
of 263,986 outputs
Outputs of similar age from BMC Cancer
#63
of 150 outputs
Altmetric has tracked 22,817,213 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,300 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,986 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 150 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.